Aastrom Biosciences, Inc. (ASTM) rated Mkt Outperform by Rodman & Renshaw
Rodman & Renshaw rated Mkt Outperform Vericel Corporation (NASDAQ: VCEL) on 07/08/2008, when the stock price was $56.00.
Since then, Vericel Corporation has lost 93.79% as of 03/02/2015's recent price of $3.48. If you would have followed this Rodman & Renshaw's recommendation on VCEL, you would have lost 93.78% of your investment in 2428 days.
Aastrom Biosciences, Inc. is a regenerative medicine company and focuses on the clinical development of autologous cell products for the repair or regeneration of multiple human tissues, based on its Tissue Repair Cell (TRC) technology. The Company?s preclinical and clinical product development programs utilize patient-derived bone marrow stem and early progenitor cell populations and are investigated for their ability to aid in the regeneration of tissues, such as cardiac, vascular and bone. TRC-based products have been used in over 350 patients, and its stages of development are Cardiac regeneration includes Cardiac Repair Cells (CRCs); Dilated cardiomyopathy (DCM) (severe heart failure); Vascular regeneration includes Vascular Repair Cells (VRCs); Critical limb ischemia (CLI); Bone regeneration includes Bone Repair Cells (BRCs); Osteonecrosis of the femoral head; Non-union fractures, and Maxillofacial.
Rodman & Renshaw
is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. We also provide research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.